| Literature DB >> 30014186 |
Courtney Heffernan1, Richard Long2,3.
Abstract
Twenty years ago, a National Consensus Conference on Tuberculosis (TB) recommended that the provinces and territories of Canada jointly declare a commitment to TB elimination with national coordination and assured funding, executed by a committee of federal and provincial/territorial representatives. Canada has committed to the global TB elimination targets set forth by the World Health Organization but lacks a coordinated response. In particular, with the exception of one published and implemented by Indigenous Services Canada, there has been no national monitoring and performance framework. Herein, we provide a commentary on the importance, to TB elimination in Canada, of developing such a framework. We invite a debate about whether more can and should be done to monitor and report for action at every jurisdictional level. Of utmost importance will be the need to achieve consensus from stakeholders about what is measured, among whom, how often, who collects and processes data, and how to respond to the successes and failures those data indicate. Insofar, as performance targets are well defined and implemented, national progress towards tuberculosis elimination should accelerate.Entities:
Keywords: Performance indicators; Public health; Tuberculosis elimination
Mesh:
Year: 2018 PMID: 30014186 PMCID: PMC6335369 DOI: 10.17269/s41997-018-0106-x
Source DB: PubMed Journal: Can J Public Health ISSN: 0008-4263
Fig. 1a National tuberculosis cases and rate of disease (2000–2016). Actual: Between 2000 and 2016, the national rate declined by 16% or ~ 1% per annum—half of the most optimistic estimates and less than a quarter of the most aggressive targets we would need to achieve in order to meet the 2035 elimination goals. b Estimated number of years (~ 85) to pre-elimination targets given a 2% per annum reduction in incidence. Optimistic: Based on conventional wisdom that once the foreign-born migrants contribute more than 70% of cases, the annual incidence, using routine or continued programming, will not decline by more than 2% per year. Foreign-born migrants have contributed > 70% of cases since 2015. c Decline in national incidence to 10/1,000,000 population by 2035. Aggressive: Ideal reduction in the annual TB incidence rate to meet pre-elimination by 2035
Proposed indicators and targets
| Indicator | Target |
|---|---|
| Incidence* | |
| • Incidence (National) | Rate of decline commensurate with 2035 pre-elimination goals |
| • Incidence (on- and off-reserve First Nations) | |
| • Incidence (Inuit Nunangat) | |
| • Incidence (Atlantic Canada) | |
| • Incidence (Quebec) | |
| • Incidence (Ontario) | |
| • Incidence (Manitoba/Saskatchewan) | |
| • Incidence (Alberta/Northwest Territories) | |
| • Incidence (British Columbia/Yukon) | |
| Laboratory reporting | |
| • Turn-around time (NAAT) | 6 days (4 days specimen collection and delivery; 2 days detection) |
| • Turn-around time (Culture) | 25 days (4 days specimen collection and delivery; 21 days to grow)—78% |
| • Proportion HIV tested | 95% |
| • Proportion of culture-positive cases with DST | 100% |
| • Proportion of culture-positive cases with genotyping | 100% |
| for smear-positive pulmonary cases † | |
| • Sputum culture and CXR, end of initial phase | 100% |
| • Sputum culture and CXR, end of continuation phase | 100% |
| Case management and treatment | |
| • Proportion of pediatric cases (< 5 years) | < 5% |
| • CB cases/w no past hx TB started on a minimum of 3 drugs | 100% |
| • FB cases/w no past hx TB started on a minimum of 4 drugs | 100% |
| • Proportion with TB-related death of preceding years’ cases | < 5% |
| for smear-positive pulmonary cases | |
| • Starting treatment within 72 h of NAAT | 90% |
| • Complete treatment within 12 months | 95% |
| Contact investigations | |
| • Close contacts of smear-positive pulmonary cases: | |
| Proportion completely assessed < 5 years of age | 100% |
| Proportion completely assessed ≥ 5 years of age | 80% |
| • Close contacts with new positive TST/TST conversion: | |
| Proportion recommended TX LTBI < 5 years of age | 100% |
| Proportion recommended TX LTBI ≥ 5 years of age | 100% |
| • Close contacts recommended TX LTBI: | |
| Proportion who start treatment < 5 years of age | 100% |
| Proportion who start treatment ≥ 5 years of age | 80% |
| • Close contacts accepting TX LTBI: | |
| Proportion who complete treatment < 5 years of age | 100% |
| Proportion who complete treatment ≥ 5 years of age | 80% |
| IRCC referrals | |
| • Proportion who initiate examination within 30 days of notification | 100% |
| • Proportion completing examination within 90 days of notification | 100% |
| • Proportion of IRCC referrals recommended TX LTBI who accept | 90% |
| • Proportion of IRCC referrals accepting TX LTBI who complete | 90% |
| CTBRS reporting | |
| • Active TB case report form (last full year) complete | 100% |
| • Treatment outcome form (next to last full year) complete | 100% |
NAAT nucleic acid amplification test, DST drug susceptibility testing, CXR chest x-ray, CB Canadian-born, FB foreign-born, TX treatment, LTBI latent tuberculosis infection, IRCC Immigration Refugee and Citizenship Canada, CTBRS Canadian Tuberculosis Reporting System
*The proposed groupings take into account persons at risk, populations, existing organizational structures, and relationships
†The initial phase of treatment refers to an intensive three-four drug treatment regimen that lasts 2 months; the continuation phase lasts 4–7 months in fully susceptible cases and is usually a two-drug regimen